Nathan Ihle

Nathan Ihle serves as Senior Vice President, Pharmaceutical Operations, at Bolt Biotherapeutics, a clinical stage biopharmaceutical company pioneering in the discovery and development of Immune-Stimulating Antibody Conjugates and other modulators of myeloid biology. In this role he is responsible for building and leading the Technical Development and Quality groups and coordinating a network of outsourced manufacturers. Prior to joining Bolt, Nathan held positions of increasing responsibility at Merck, PathoGenesis, Celltech, Seattle Genetics, and Immunomedics. While at Seattle Genetics he led the CMC team responsible for the development and commercialization of ADCETRIS® (brentuximab vedotin). Throughout his career, Dr. Ihle has been a key leader in the development of six approved drugs and numerous ADCs currently in clinical development. He is trained as a synthetic organic chemist, with degrees from Whitman College and Stanford University. He conducted postdoctoral research at the University of California, Berkeley.

Appearances

This speaker has made no appearances.